SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Blueberry Therapeutics Ltd.. (8/13/15). "Press Release: Andrew Kay Appointed Chairman of the Board at Blueberry Therapeutics".

Organisations Organisation Blueberry Therapeutics Ltd.
  Organisation 2 Algeta ASA (Oslo Stock Exchange: ALGETA)
  Group Bayer (Group)
Products Product Xofigo® (Alpharadin™)
  Product 2 pharmaceutical
Index term Index term Algeta–Bayer: investment, 201311– acquisition proposal by Bayer NOK362/share valuing Algeta equity at €2.1b
Person Person Kay, Andrew (Algeta 200901 CEO before Renovo plc since 2003 before Novartis)

Blueberry are delighted to welcome Mr. Andrew Kay to Blueberry Therapeutics as Chairman of the Board. Andrew brings more than 30 years of commercial and leadership experience in the pharmaceutical sector, latest as CEO of Algeta ASA. During Andrew’s leadership, Algeta’s lead product, Xofigo, was approved by the FDA and EMA for the treatment of bone metastases in castration resistant prostate cancer patients. In February 2014, Algeta was acquired by its partner Bayer AG for USD 2.9 billion. Andrew’s previous roles include Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots.

Record changed: 2018-08-19


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Blueberry Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUK] – The Business Web Portal 600x80px

» top